Meta-Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes.

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2024-11-04 DOI:10.1111/apt.18373

Sahand Karimzadhagh, Elahe Abbaspour, Maryam Shahriarinamin, Pourya Shamsi, Selvana Poursadrolah, Mehrdad Khorasani, Mahzad Daghighi, Arash Malek, Jouan Taheri Talesh, Govind K Makharia, Mohammad Rostami-Nejad

{"title":"Meta-Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes.","authors":"Sahand Karimzadhagh, Elahe Abbaspour, Maryam Shahriarinamin, Pourya Shamsi, Selvana Poursadrolah, Mehrdad Khorasani, Mahzad Daghighi, Arash Malek, Jouan Taheri Talesh, Govind K Makharia, Mohammad Rostami-Nejad","doi":"10.1111/apt.18373","DOIUrl":null,"url":null,"abstract":"Background: Coeliac disease (CD) is common in patients with type 1 diabetes (T1D), but prevalence varies globally due to differing screening protocols. There have been substantial changes in screening guidelines over the past two decades.Aim: To evaluate CD prevalence in patients with T1D, focusing on screening studies using antitissue transglutaminase (anti-tTG) antibody.Methods: We searched PubMed, Web of Science, Embase and Scopus for studies published up to 11 December 2023 using keywords related to CD and diabetes. We used random-effects models for overall prevalence and all subgroups, with heterogeneity assessed using Cochran's Q test and the I2 statistic performed in STATA 18.Results: We included 106 articles involving 65,102 T1D patients across 40 countries. The pooled CD seroprevalence and confirmed CD prevalence were 9% (95% confidence interval, CI, 8%-10%) and 6% (95% CI 5%-7%), respectively. The prevalence was higher in females and children. Denmark, Saudi Arabia and Libya exhibited the highest prevalence (11%), followed by India and Egypt (10%). Belgium, France, Germany, South Africa and the United States had the lowest prevalence (2%). High-income countries showed significantly a lower CD prevalence than middle-income countries (p = 0.03). Meta-regression based on the Human Development Index (HDI) indicated that countries with higher HDI have lower seroprevalence and confirmed CD prevalence.Conclusion: Approximately 1 in 16 patients globally and 1 in 12 patients in Asia and the Middle East with T1D has CD. We suggest that all patients with T1D should be screened for CD.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.18373","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Coeliac disease (CD) is common in patients with type 1 diabetes (T1D), but prevalence varies globally due to differing screening protocols. There have been substantial changes in screening guidelines over the past two decades.

Aim: To evaluate CD prevalence in patients with T1D, focusing on screening studies using antitissue transglutaminase (anti-tTG) antibody.

Methods: We searched PubMed, Web of Science, Embase and Scopus for studies published up to 11 December 2023 using keywords related to CD and diabetes. We used random-effects models for overall prevalence and all subgroups, with heterogeneity assessed using Cochran's Q test and the I² statistic performed in STATA 18.

Results: We included 106 articles involving 65,102 T1D patients across 40 countries. The pooled CD seroprevalence and confirmed CD prevalence were 9% (95% confidence interval, CI, 8%-10%) and 6% (95% CI 5%-7%), respectively. The prevalence was higher in females and children. Denmark, Saudi Arabia and Libya exhibited the highest prevalence (11%), followed by India and Egypt (10%). Belgium, France, Germany, South Africa and the United States had the lowest prevalence (2%). High-income countries showed significantly a lower CD prevalence than middle-income countries (p = 0.03). Meta-regression based on the Human Development Index (HDI) indicated that countries with higher HDI have lower seroprevalence and confirmed CD prevalence.

Conclusion: Approximately 1 in 16 patients globally and 1 in 12 patients in Asia and the Middle East with T1D has CD. We suggest that all patients with T1D should be screened for CD.

Abstract Image

查看原文本刊更多论文

元分析：1型糖尿病患者乳糜泻的全球患病率。

背景：乳糜泻（CD）在 1 型糖尿病（T1D）患者中很常见，但由于筛查方案不同，全球的患病率也不尽相同。目的：评估 CD 在 T1D 患者中的患病率，重点关注使用抗组织转谷氨酰胺酶（抗-tTG）抗体进行的筛查研究：我们使用 CD 和糖尿病相关关键词检索了 PubMed、Web of Science、Embase 和 Scopus 上截至 2023 年 12 月 11 日发表的研究。我们使用随机效应模型对总体患病率和所有亚组进行了分析，并使用Cochran's Q检验和STATA 18中的I2统计量对异质性进行了评估：我们共纳入了 106 篇文章，涉及 40 个国家的 65,102 名 T1D 患者。汇总的CD血清流行率和确诊的CD流行率分别为9%（95%置信区间，CI，8%-10%）和6%（95% CI，5%-7%）。女性和儿童的发病率较高。丹麦、沙特阿拉伯和利比亚的患病率最高（11%），其次是印度和埃及（10%）。比利时、法国、德国、南非和美国的患病率最低（2%）。高收入国家的 CD 患病率明显低于中等收入国家（p = 0.03）。基于人类发展指数（HDI）的元回归表明，人类发展指数较高的国家血清阳性反应率和确诊的 CD 感染率较低：全球每 16 名 T1D 患者中约有 1 人患有 CD，亚洲和中东每 12 名患者中约有 1 人患有 CD。我们建议对所有 T1D 患者进行 CD 筛查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.